

<p><b>GSK Medicine:</b> Abacavir, amprenavir, abacavir/lamivudine/zidovudine, Zidovudine, Lamivudine, abacavir/lamivudine, zidovudine/lamivudine, fosamprenavir</p>
<p><b>Study No.:</b> WEUSKOP3368/EPI40320/ WWE112877</p>
<p><b>Title 1:</b> Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study</p>
<p><b>Title 2:</b> Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration</p>
<p><b>Title 3:</b> Class of antiretroviral drugs and the risk of myocardial infarction. The DAD Study Group</p>
<p><b>Title 4:</b> Predicting the risk of coronary heart disease (CHD) in HIV-infected patients: The D:A:D CHD risk equation</p>
<p><b>Title 5:</b> Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study</p>
<p><b>Indication:</b> HIV</p>
<p><b>Study Investigators/Centers:</b> D.A.D Study group, Centre for Viral Disease/KMA and Copenhagen HIV Programme, Rigshospitalet and University of Copenhagen, Panum Institute</p>
<p><b>Reference 1:</b> Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. JID 2010;201:318-30</p>
<p><b>Reference 2:</b> D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417–26.</p>
<p><b>Reference 3:</b> The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35.</p>
<p><b>Reference 4:</b> Friis-Møller N, Thiébaud R, Reiss P, et al. Predicting the risk of coronary heart disease (CHD) in HIV-infected patients: The D:A:D CHD risk equation. Session 145, abstract 808. 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections. February 25-28, 2007. Los Angeles, California.</p>
<p><b>Reference 5:</b> Law M, Friis-Møller N, Weber R, et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Medicine 2003;4:1-10.</p>